FosB transcription factor regulates COX‑2 expression in colorectal cancer cells without affecting PGE2 expression

Cervantes‑Madrid,Diana   Lizeth; Nagi,Sabah; Asting Gustafsson,Annika

doi:10.3892/ol.2017.5571

FosB transcription factor regulates COX‑2 expression in colorectal cancer cells without affecting PGE2 expression

Authors:
- Diana Lizeth Cervantes‑Madrid
- Sabah Nagi
- Annika Asting Gustafsson
View Affiliations

Affiliations: Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, 413 45 Gothenburg, Sweden
Published online on: January 4, 2017 https://doi.org/10.3892/ol.2017.5571
Pages: 1411-1416

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The expression levels of cyclooxygenase (COX)‑2 and the prostaglandin E2 (PGE2) content have been associated with poor prognosis in patients with colorectal cancer (CRC). There is a strong correlation between COX‑2 expression and PGE2 production in tissues from CRC patients, suggesting an important role for COX‑2 on the regulation of PGE2 production. Previous studies by the present authors, where CRC patients were divided into high‑ or low‑COX‑2 expressing tumors, displayed important differences in the expression levels of several transcription factors involved in carcinogenesis. Among them, FBJ murine osteosarcoma viral oncogene homolog B (FosB), which is a member of the activator protein‑1 complex, was the highest upregulated transcription factor in patients with high expression levels of COX‑2. The present study aimed to investigate the role of FosB on the COX‑2/PGE2 axis in CRC cells with high COX‑2 expression levels. Interference RNA technology was used to knockdown FosB expression in HCA‑7 cells, and 72 h later the messenger (m)RNA expression levels of COX‑1 and COX‑2, as well as the PGE2 content, were measured. The results indicated that FosB knockdown decreased the expression levels of COX‑2 but did not affect the PGE2 content or the mRNA expression levels of COX‑1. The present findings suggest an important role for FosB on the regulation of COX‑2 expression, but no effect on the regulation of the PGE2 levels. In addition, the present results imply independent regulatory mechanisms for COX‑2 expression and PGE2 content.

View Figures

View References

1	International Agency for Research on Cancer, . GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_population.aspxAccessed January 5, 2016.
2	Coussens LM and Werb Z: Inflammation and cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
3	Lutgens MW, van Oijen MG, van der Heijden GJ, Vleggaar FP, Siersema PD and Oldenburg B: Declining risk of colorectal cancer in inflammatory bowel disease: An updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis. 19:789–799. 2013. View Article : Google Scholar : PubMed/NCBI
4	Lundholm K, Gelin J, Hyltander A, Lönnroth C, Sandström R, Svaninger G, Körner U, Gülich M, Kärrefors I and Norli B: Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res. 54:5602–5606. 1994.PubMed/NCBI
5	Thun MJ, Namboodiri MM and Heath CW Jr: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med. 325:1593–1596. 1991. View Article : Google Scholar : PubMed/NCBI
6	Narisawa T, Sato M, Tani M, Kudo T, Takahashi T and Goto A: Inhibition of development of methylnitrosourea-induced rat colon tumors by indomethacin treatment. Cancer Res. 41:1954–1957. 1981.PubMed/NCBI
7	Rao CV, Tokumo K, Rigotty J, Zang E, Kelloff G and Reddy BS: Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, alpha-difluoromethylornithine, 16 alpha-fluoro-5-androsten-17-one, and ellagic acid individually and in combination. Cancer Res. 51:4528–4534. 1991.PubMed/NCBI
8	Moorghen M, Ince P, Finney KJ, Sunter JP, Appleton DR and Watson AJ: A protective effect of sulindac against chemically-induced primary colonic tumours in mice. J Pathol. 156:341–347. 1988. View Article : Google Scholar : PubMed/NCBI
9	Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 231:232–235. 1971. View Article : Google Scholar : PubMed/NCBI
10	Rouzer CA and Marnett LJ: Cyclooxygenases: Structural and functional insights. J Lipid Res. 50:Suppl. S29–S34. 2009. View Article : Google Scholar : PubMed/NCBI
11	Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, Kimura S, Kato H, Kondo M and Hla T: Expression of cyclooxygenase-1 and −2 in human colorectal cancer. Cancer Res. 55:3785–3789. 1995.PubMed/NCBI
12	Sheehan KM, Sheahan K, O'Donoghue DP, MacSweeney F, Conroy RM, Fitzgerald DJ and Murray FE: The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA. 282:1254–1258. 1999. View Article : Google Scholar : PubMed/NCBI
13	Kunzmann AT, Murray LJ, Cardwell CR, McShane CM, McMenamin UC and Cantwell MM: PTGS2 (cyclooxigenase-2) expression and survival among colorectal cancer patients: A systematic review. Cancer Epidemiol Biomarkers Prev. 22:1490–1497. 2013. View Article : Google Scholar : PubMed/NCBI
14	Cahlin C, Lönnroth C, Arvidsson A, Nordgren S and Lundholm K: Growth associated proteins in tumor cells and stroma related to disease progression of colon cancer accounting for tumor tissue PGE2 content. Int J Oncol. 32:909–918. 2008.PubMed/NCBI
15	Wang D and DuBois RN: An inflammatory mediator, prostaglandin E2, in colorectal cancer. Cancer J. 19:502–510. 2013. View Article : Google Scholar : PubMed/NCBI
16	Rigas B, Goldman IS and Levine L: Altered eicosanoid levels in human colon cancer. J Lab Clin Med. 122:518–523. 1993.PubMed/NCBI
17	Pugh S and Thomas GA: Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2. Gut. 35:675–678. 1994. View Article : Google Scholar : PubMed/NCBI
18	Yoshimatsu K, Golijanin D, Paty PB, Soslow RA, Jakobsson PJ, DeLellis RA, Subbaramaiah K and Dannenberg AJ: Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. Clin Cancer Res. 7:3971–3976. 2001.PubMed/NCBI
19	Asting AG, Carén H, Andersson M, Lönnroth C, Lagerstedt K and Lundholm K: COX-2 gene expression in colon cancer tissue related to regulating factors and promoter methylation status. BMC Cancer. 11:2382011. View Article : Google Scholar : PubMed/NCBI
20	Ashida R, Tominaga K, Sasaki E, Watanabe T, Fujiwara Y, Oshitani N, Higuchi K, Mitsuyama S, Iwao H and Arakawa T: AP-1 and colorectal cancer. Inflammopharmacology. 13:113–125. 2005. View Article : Google Scholar : PubMed/NCBI
21	Yang F, Nam S, Zhao R, Tian Y, Liu L, Horne DA and Jove R: A novel synthetic derivative of the natural product berbamine inhibits cell viability and induces apoptosis of human osteosarcoma cells, associated with activation of JNK/AP-1 signaling. Cancer Biol Ther. 14:1024–1031. 2013. View Article : Google Scholar : PubMed/NCBI
22	Shaulian E and Karin M: AP-1 in cell proliferation and survival. Oncogene. 20:2390–2400. 2001. View Article : Google Scholar : PubMed/NCBI
23	Kovary K, Rizzo CA, Ryseck RP, Noguchi T, Raynoschek C, Pelosin JM and Bravo R: Constitutive expression of FosB and its short form, FosB/SF, induces malignant cell transformation in rat-A1 cells. New Biol. 3:870–879. 1991.PubMed/NCBI
24	Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, Imamura Y, Qian ZR, Baba Y, Shima K, et al: Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med. 367:1596–1606. 2012. View Article : Google Scholar : PubMed/NCBI
25	Chan AT, Ogino S and Fuchs CS: Aspirin use and survival after diagnosis of colorectal cancer. JAMA. 302:649–658. 2009. View Article : Google Scholar : PubMed/NCBI
26	Chan AT, Ogino S and Fuchs CS: Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med. 356:2131–2142. 2007. View Article : Google Scholar : PubMed/NCBI
27	Babu RL, Kumar M Naveen, Patil RH, Devaraju KS, Ramesh GT and Sharma SC: Effect of estrogen and tamoxifen on the expression pattern of AP-1 factors in MCF-7 cells: Role of c-Jun, c-Fos, and Fra-1 in cell cycle regulation. Mol Cell Biochem. 380:143–151. 2013. View Article : Google Scholar : PubMed/NCBI
28	Harwood FG, Kasibhatla S, Petak I, Vernes R, Green DR and Houghton JA: Regulation of FasL by NF-kappaB and AP-1 in Fas-dependent thymineless death of human colon carcinoma cells. J Biol Chem. 275:10023–10029. 2000. View Article : Google Scholar : PubMed/NCBI
29	Kim YJ, Yoon SY, Kim JT, Choi SC, Lim JS, Kim JH, Song EY, Lee HG, Choi I and Kim JW: NDRG2 suppresses cell proliferation through down-regulation of AP-1 activity in human colon carcinoma cells. Int J Cancer. 124:7–15. 2009. View Article : Google Scholar : PubMed/NCBI
30	Rivat C, Le Floch N, Sabbah M, Teyrol I, Redeuilh G, Bruyneel E, Mareel M, Matrisian LM, Crawford HC, Gespach C and Attoub S: Synergistic cooperation between the AP-1 and LEF-1 transcription factors in the activation of the matrilysin promoter by the src oncogene: Implications in cellular invasion. FASEB J. 17:1721–1723. 2003.PubMed/NCBI
31	Xue X and Shah YM: Hypoxia-inducible factor-2α is essential in activating the COX-2/mPGES-1/PGE2 signaling axis in colon cancer. Carcinogenesis. 34:163–169. 2013. View Article : Google Scholar : PubMed/NCBI
32	Xue X, Taylor M, Anderson E, Hao C, Qu A, Greenson JK, Zimmermann EM, Gonzalez FJ and Shah YM: Hypoxia-inducible factor-2α activation promotes colorectal cancer progression by dysregulating iron homeostasis. Cancer Res. 72:2285–2293. 2012. View Article : Google Scholar : PubMed/NCBI
33	Stamatakis K, Jimenez-Martinez M, Jimenez-Segovia A, Chico-Calero I, Conde E, Galán-Martínez J, Ruiz J, Pascual A, Barrocal B, López-Pérez R, et al: Prostaglandins induce early growth response 1 transcription factor mediated microsomal prostaglandin E2 synthase up-regulation for colorectal cancer progression. Oncotarget. 6:39941–39959. 2015.PubMed/NCBI
34	Seo T, Tatsuguchi A, Shinji S, Yonezawa M, Mitsui K, Tanaka S, Fujimori S, Gudis K, Fukuda Y and Sakamoto C: Microsomal prostaglandin E synthase protein levels correlate with prognosis in colorectal cancer patients. Virchows Arch. 454:667–676. 2009. View Article : Google Scholar : PubMed/NCBI
35	Almendingen K, Larsen LN, Fausa O, Bratlie J, Høstmark AT and Aabakken L: Selective COX-2 inhibition affects fatty acids, but not COX mRNA expression in patients with FAP. Fam Cancer. 9:571–580. 2010. View Article : Google Scholar : PubMed/NCBI